ArticleAnnals of translational medicine2020
Article in Annals of translational medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 15 citations in OpenAlex.
- Investigating theResearch in pharmaceutical sciences · 2026Article
- VAMP4 in hypoxic adipose stem cell exosomes alleviates ischemia-reperfusion injury.Cellular and molecular life sciences : CMLS · 2025Article
- Donor adipose-derived stromal cells are vasoprotectant but unable to revert acute rejection in rodent vascularized composite allotransplants.Frontiers in immunology · 2025Article
- Adipose-Derived Stem Cells: Angiogenetic Potential and Utility in Tissue Engineering.International journal of molecular sciences · 2024Review
- Therapeutic angiogenesis and tissue revascularization in ischemic vascular disease.Journal of biological engineering · 2023Review
- Toward transplantation tolerance with adipose tissue-derived therapeutics.Frontiers in immunology · 2023Review
- Overexpression of integrin βAnnals of translational medicine · 2022Article
- Mouse Neural Stem Cell Differentiation and Human Adipose Mesenchymal Stem Cell Transdifferentiation Into Neuron- and Oligodendrocyte-like Cells With Myelination Potential.Stem cell reviews and reports · 2022Article
- Improving the ischemia-reperfusion injury in vascularized composite allotransplantation: Clinical experience and experimental implications.Frontiers in immunology · 2022Review
- Adipose-Derived Stem Cell: "Treat or Trick".Biomedicines · 2021Review
- Review
- Scaffold strategies combined with mesenchymal stem cells in vaginal construction: a review.Cell regeneration (London, England) · 2021Review
- Adipose-derived cellular therapies prolong graft survival in an allogenic hind limb transplantation model.Stem cell research & therapy · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVascularized composite tissue allotransplantation (VCA) has increasingly been adopted for the reconstruction of tissues following severe injury. However, the side effects of the post-operative use of immunosuppressants may outweigh the benefits of VCA. In order to overcome this obstacle,
methodsA hind-limb allotransplantation model of Brown-Norway to Lewis rats was established, and the allografts were infused with adipose-derived stem cells (ADSCs) and hypoxia primed ADSCs, which were injected through the vascular system along with short-term immunosuppressant treatment. The rejection-free survival of the allografts was monitored, and the histopathological examination of allografts was performed. The peripheral T lymphocytes and cytokines were analyzed using flow cytometry and ELISA, while Tregs infiltration in allotissue was detected using immunohistochemical staining (IHC).
resultsThis study found that the
conclusionsThe
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.